ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Roque Pifarré
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Terrell, M. R.
Right arrow Articles by Pifarré, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terrell, M. R.
Right arrow Articles by Pifarré, R.

Ann Thorac Surg 1996;62:506-511
© 1996 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Efficacy of Aprotinin With Various Anticoagulant Agents in Cardiopulmonary Bypass

Mark R. Terrell, MD, Jeanine M. Walenga, PhD, Michael J. Koza, BS, Roque Pifarré, MD

Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois

Accepted for publication March 26, 1996.

Background. Aprotinin has recently been approved for clinical use in cardiopulmonary bypass. Although unfractionated heparin has been the only anticoagulant widely used for cardiopulmonary bypass, disadvantages involving heparin have led to ongoing investigations of alternative anticoagulant agents.

Methods. The objective of this study was to evaluate the efficacy of aprotinin in combination with other anticoagulant agents, specifically low molecular weight heparin and recombinant hirudin, using a dog model of cardiopulmonary bypass.

Results. The blood conservation resulting from the use of aprotinin was observed only with unfractionated heparin. Efficacy of anticoagulation as measured by protein deposits in the bypass circuit filter revealed an unexpected reduction in the quantity of deposits when aprotinin was used in combination with low molecular weight heparin.

Conclusions. As alternative anticoagulant agents are sought, the potential benefits of aprotinin in the reduction of operative blood loss must be evaluated independently for each anticoagulant agent.




This article has been cited by other articles:


Home page
 PerfusionHome page
M. Wallock, W. P Jeske, M. Bakhos, and J. M Walenga
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test
Perfusion, March 1, 2001; 16(2): 147 - 153.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. P. Carrel, M. Schwanda, P. R. Vogt, and M. I. Turina
Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only
Ann. Thorac. Surg., July 1, 1998; 66(1): 153 - 158.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.